Loading...
If your product does not perform as described on this datasheet, we will refund or replace your product...
Read our guarantee »Products:Cell Biology >> Cell Cycle >> Cell Cycle Inhibitors >> Rb
Anti-Rb (phospho T821) antibody
See all Rb products (41) ...
Rabbit polyclonal to Rb (phospho T821)
Reacts with
Mouse, Human
Predicted to work with
Rat
Synthetic peptide (Human) derived from a region of human Rb that contains threonine 821 (based on Swiss Protein database, accession number P06400). The sequence is conserved in human, mouse and rat.
Jurkat cells in high growth phase.
Liquid
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Preservative: 0.05% Sodium Azide
Constituents: 50% Glycerol, PBS, 1mg/ml BSA. pH 7.3
Concentration information loading...
Immunogen affinity purified
Purified from rabbit serum by sequential epitope-specific chromatography. The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated Rb protein. The final product is generated by affinity chromatography using a Rb-derived peptide that is phosphorylated at threonine 821.
Polyclonal
IgG
Cancer >> Oncoproteins/suppressors >> Tumor suppressors >> Rb family
Cancer >> Oncoproteins/suppressors >> Tumor suppressors
Epigenetics and Nuclear Signaling >> Transcription >> Cancer susceptibility >> Tumor Suppressors
Cell Biology >> Cell Cycle >> Cell Cycle Inhibitors >> Rb
Western blot - Rb (phospho T821) antibody (ab4787)
(enlarge)
Our Abpromise guarantee covers the use of ab4787 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: 1/1000. Detects a band of approximately 120 kDa (predicted molecular weight: 106 kDa). Can be blocked with Rb peptide - phospho T821 (phospho and non-phospho pair).
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Key regulator of entry into cell division that acts as a tumor suppressor. Acts as a transcription repressor of E2F1 target genes. The underphosphorylated, active form of RB1 interacts with E2F1 and represses its transcription activity, leading to cell cycle arrest. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity). In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1's activity.
Expressed in the retina.
Defects in RB1 are the cause of childhood cancer retinoblastoma (RB) [MIM:180200]. RB is a congenital malignant tumor that arises from the nuclear layers of the retina. It occurs in about 1:20'000 live births and represents about 2% of childhood malignancies. It is bilateral in about 30% of cases. Although most RB appear sporadically, about 20% are transmitted as an autosomal dominant trait with incomplete penetrance. The diagnosis is usually made before the age of 2 years when strabismus or a gray to yellow reflex from pupil ('cat eye') is investigated.
Defects in RB1 are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
Defects in RB1 are a cause of osteogenic sarcoma (OSRC) [MIM:259500].
Belongs to the retinoblastoma protein (RB) family.
The Pocket domain binds to the threonine-phosphorylated domain C, thereby preventing interaction with heterodimeric E2F/DP transcription factor complexes.
Phosphorylated in G1, thereby releasing E2F1 which is then able to activate cell growth. Dephosphorylated at the late M phase. SV40 large T antigen, HPV E7 and adenovirus E1A bind to the underphosphorylated, active form of pRb. Phosphorylation at Thr-821 and Thr-826 promotes interaction between the C-terminal domain C and the Pocket domain, and thereby inhibits interactions with heterodimeric E2F/DP transcription factor complexes. Dephosphorylated at Ser-795 by calcineruin upon calcium stimulation.
N-terminus is methylated by METTL11A/NTM1 (By similarity). Monomethylated at Lys-860 by SMYD2, promoting interaction with L3MBTL1.
Nucleus.
Target information above from: UniProt accessionP06400
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Western blot - Rb (phospho T821) antibody (ab4787)

Predicted band size : 106 kDa
Peptide Competition: Cell extracts prepared from Jurkat cells in high growth phase were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. Membranes were incubated with 0.50 µg/mL ab4787, following prior incubation in the: absence of the phosphopeptide immunogen (1), a generic phosphothreonine containing peptide (2), the non phosphopeptide corresponding to the phosphopeptide immunogen (3), or the presence of the phosphopeptide immunogen (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and bands were detected using the Tropix WesternStar detection method. The data show that only the phosphopeptide corresponding to this site blocks the antibody signal, demonstrating the specificity of the ab4787 antibody for this epitope.
This product has been referenced in:
See all 4 publications for this product
Publishing research using ab4787? Please let us know so that we can cite the reference in this datasheet
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:

Predicted band size : 106 kDa
Peptide Competition: Cell extracts prepared from Jurkat cells in high growth phase were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. Membranes were incubated with 0.50 µg/mL ab4787, following prior incubation in the: absence of the phosphopeptide immunogen (1), a generic phosphothreonine containing peptide (2), the non phosphopeptide corresponding to the phosphopeptide immunogen (3), or the presence of the phosphopeptide immunogen (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and bands were detected using the Tropix WesternStar detection method. The data show that only the phosphopeptide corresponding to this site blocks the antibody signal, demonstrating the specificity of the ab4787 antibody for this epitope.
0
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Call 01223 696 000 or contact us
